Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers
NCT ID: NCT01707940
Last Updated: 2013-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2012-10-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823
NCT01189175
Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects
NCT01787032
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the Blood
NCT03782987
A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood
NCT06041438
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
NCT02513446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BI 144807
subjects receive an oral single dose of BI 144807
BI 144807
BI144807 oral solution, intermediate dose
BI 144807 plus Ketoconazole
subjects receive bid ketoconazole plus an oral single dose of BI 144807
Ketoconazole
Ketoconazole 400 mg / day
BI 144807
BI144807 oral solution, intermediate dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketoconazole
Ketoconazole 400 mg / day
BI 144807
BI144807 oral solution, intermediate dose
BI 144807
BI144807 oral solution, intermediate dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1313.7.1 Boehringer Ingelheim Investigational Site
Biberach, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-003225-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1313.7
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.